Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Profound Medical Corp.NASDAQ: PROF
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$7.81M, compared with -$10.97M a year earlier. Trailing-twelve-month EBITDA was -$37.85M.
Context
- EBITDA amounted to 252.8% of revenue in FY2025, up 1.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$26.4M (+36.2%) for the fiscal year ending Dec 2026, a step up from the -61.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.81M-6.0% QoQ
- Last fiscal yearDec 2025
- -$41.41M-61.8% YoY
- LTMMar 2026
- -$37.85M+9.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.8% | +37.2% | +8.4 pp |
| 1 year | -61.8% | +36.2% | +98.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (41.41M) USD
- Year-over-year change
- -61.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.41M) | -61.8% |
| FY2024 | 2024-12-31 | (25.59M) | +4.4% |
| FY2023 | 2023-12-31 | (26.78M) | -0.7% |
| FY2022 | 2022-12-31 | (26.6M) | +7.1% |
| FY2021 | 2021-12-31 | (28.65M) | — |
EBITDA vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 EBITDA of -$37.85M is the 5th highest of the 11 companies compared; the peer median is -$46.13M.
- Its year-over-year change of +9.1% is the 4th highest of 11, against a peer median of -2.7%.
- EBITDA amounts to 200.6% of revenue for PROF, versus a peer median of 83.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.96M | +165.0% | — | 58.8% | |
| LTM Mar 2026 | -$20.95M | +5.5% | — | 46.7% | |
| LTM Mar 2026 | -$25.7M | +34.0% | — | 17.0% | |
| LTM Mar 2026 | -$34.64M | +5.7% | — | 107.3% | |
| LTM Mar 2026 | -$37.85M | +9.1% | — | 200.6% | |
| LTM Mar 2026 | -$43.26M | -365.8% | — | 40.4% | |
| LTM Dec 2025 | -$49M | -11.0% | — | 376.3% | |
| LTM Mar 2026 | -$51.68M | +9.1% | — | 45.4% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -$92.94M | -14.3% | — | 5021.0% |
| LTM Mar 2026 | -$110.64M | -31.7% | — | 17902.8% | |
| LTM Mar 2026 | -$262.46M | -2046.7% | — | 8872.8% | |
| Peer median (excluding PROF) | -$46.13M | -2.7% | — | 83.1% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.87M | 6.68M | 7.2M | 10.17M | 16.38M |
| Cost of Revenue | 3.92M | 3.66M | 2.82M | 3.47M | 4.79M |
| Gross Profit | 2.95M | 3.02M | 4.38M | 6.7M | 11.59M |
| Gross Margin | 43.0% | 45.2% | 60.9% | 65.9% | 70.8% |
| Research & Development | 15.28M | 14.69M | 14.38M | 16.15M | 20.96M |
| Selling, General & Admin | 17.97M | 17.93M | 18.62M | 22.02M | 32.61M |
| Operating Expenses | 33.24M | 35.15M | 33M | 38.17M | 53.57M |
| Depreciation & Amortization | 1.88M | 1.6M | 1.15M | 891.06K | 569.8K |
| EBITDA | (28.65M) | (26.6M) | (26.78M) | (25.59M) | (41.41M) |
| EBITDA Margin | -416.8% | -398.2% | -372.0% | -251.7% | -252.8% |
| Operating Income | (30.29M) | (32.13M) | (28.62M) | (31.47M) | (41.98M) |
| Operating Margin | -440.7% | -480.9% | -397.5% | -309.6% | -256.3% |
| Interest Income | 203.2K | 1.05M | 1.64M | 1.37M | 1.09M |
| Interest Expense | 66.41K | 167.11K | 770K | 0 | 0 |
| Other Income / Expenses | (303K) | 3.74M | (81K) | 4.99M | (1.08M) |
| Income Before Tax | (30.59M) | (28.38M) | (28.7M) | (26.48M) | (43.06M) |
| Pre-Tax Margin | -445.1% | -424.8% | -398.6% | -260.5% | -262.9% |
| Income Tax Expense | 105K | 287K | (128K) | (1.9K) | 256.41K |
| Net Income | (30.7M) | (28.67M) | (28.57M) | (26.48M) | (43.32M) |
| Net Margin | -446.7% | -429.1% | -396.8% | -260.4% | -264.4% |
| EPS (Basic) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| EPS (Diluted) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| Weighted Avg Shares | 20.46M | 20.83M | 21.18M | 24.77M | 30.23M |
| Weighted Avg Shares (Diluted) | 20.47M | 20.83M | 21.18M | 24.77M | 30.23M |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.